RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Ronnie Maitra
Experts

Rangan (Ronnie) Maitra

Research Pharmacologist

Education

Postdoctoral Fellowship, National Cancer Institute, Laboratory of Molecular Biology, NIH
PhD, Pharmacology & Toxicology, Dartmouth Medical School
BS, Chemistry (cum laude), Angelo State University.

Ronnie Maitra, PhD, conducts preclinical drug discovery research related to metabolic syndrome and liver disease. His work in pharmacology has included studying the mechanisms of chemotherapy-induced differential regulation of ABC transporters CFTR and P-glycoprotein as well as preclinical drug discovery research related to cystic fibrosis, cannabinoid receptors, and alcohol-induced liver disease.

Previous to his work at RTI, Dr. Maitra was employed at Paradigm Genetics as the group leader of experimental biology, where his research focused on the discovery of predictive disease-related biomarkers using a systems biology approach.

Expertise
  • Molecular pharmacology of drug targets, particularly ion channels (CFTR) and G protein-coupled receptors (cannabinoid receptors and APJ)
  • Translational research including assay development and ligand discovery
  • In vitro ADMET and PD research and services to facilitate lead optimization and candidate selection

Publications

View All Publications
Article

Novel peripherally selective cannabinoid receptor 1 neutral antagonist improves metabolic dysfunction-associated steatotic liver disease in mice

September 2024
Article

The monoacylglycerol lipase inhibitor ABX-1431 does not improve alcoholic liver disease

August 2024
Patent

Heterocyclic apelin receptor (APJ) agonists and uses thereof

March 2024
Article

Discovery of 1,3-disubstituted pyrazole peripheral cannabinoid receptor partial agonists

September 2023

Related Capabilities

Focus Area

Transformative Health Research for All
Solution

Drug Metabolism and Pharmacokinetics (DMPK)
Solution

In Vitro Pharmacology, Bioassay Development, and High-Throughput Screening (HTS)

Get in Touch

To speak to this expert or inquire about RTI services, you can reach us at +1 919 541 6000 or use the contact form below. For media inquiries, please reach out to our Media Relations team at news@rti.org.

Blue background circle graphics